Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
IRLAB Therapeutics AB
AB
Active
Org 5569314692
Arvid Wallgrens Backe 20, 413 46
Göteborg
Activities of head offices
·
NACE 7010
Est. 2013 · 13 years old
5-9 employees
Monitor
Share
Sweden
/
Companies
/
Activities of head offices
/
IRLAB Therapeutics AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
7M
6M
4M
2M
0M
2020: 3M
3M
2020
2021: 4M (+33% vs 2020)
4M
+33%
2021
2022: 5M (+25% vs 2021)
5M
+25%
2022
2023: 6M (+20% vs 2022)
6M
+20%
2023
2024: 6M (0% vs 2023)
6M
0%
2024
EBITDA
SEK millions
0M
-10M
-20M
-30M
-40M
2020: -13M
-13M
2020
2021: -21M (-62% vs 2020)
-21M
-62%
2021
2022: -22M (-5% vs 2021)
-22M
-5%
2022
2023: -32M (-45% vs 2022)
-32M
-45%
2023
2024: -18M (+44% vs 2023)
-18M
+44%
2024
Income statement
SEK thousands
Item
2024
2023
2022
2021
2020
Revenue
5 521
5 658
4 531
4 059
3 274
Staff expenses
—
—
—
—
—
EBITDA
−18 277
−31 509
−22 058
−21 451
−12 572
Depreciation & amort.
−0
−0
−25
−0
−0
EBIT
−18 277
−31 509
−22 083
−21 451
−12 572
Net financials
−28 538
1 547
−7
−5
−35 000
Profit before tax
−46 815
−29 962
−22 090
−21 454
−197 572
Tax
−0
−0
−0
−0
−0
Net profit
−46 815
−29 962
−22 090
−21 454
−197 572
Balance sheet
SEK thousands
Item
2024
2023
2022
2021
2020
Total assets
428 173
450 742
451 669
465 045
591 246
Equity
368 932
415 747
442 917
460 250
481 884
Long-term debt
0
24 511
0
0
0
Short-term debt
59 241
10 486
8 752
4 795
109 362
Total debt
59 241
34 997
8 752
4 795
109 362
Financial ratios
5-year trend
EBITDA margin
−331,0 %
This company
15,8 %
Market median
This company
Market median
>999% below market
2020
2024
Equity ratio
86,2 %
This company
38,2 %
Market median
This company
Market median
126% above market
2020
2024
Return on equity
−12,7 %
This company
18,4 %
Market median
This company
Market median
169% below market
2020
2024
Net profit margin
−847,9 %
This company
8,1 %
Market median
This company
Market median
>999% below market
2020
2024
Asset turnover
0,01×
This company
1,12×
Market median
This company
Market median
99% below market
2020
2024
Debt / equity
0,16×
This company
0,62×
Market median
This company
Market median
74% below market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
More on IRLAB Therapeutics AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
